Traduction de «evidence from a metaepidemiologic » (Français → Néerlandais) :

L, et al. Single-center trials show larger treatment effects than multicenter trials: evidence from a metaepidemiologic study.
L, et al. Single-center trials show larger treatment effects than multicenter trials: evidence from a meta-epidemiologic study.

Caraceni A, Hanks G, Kaasa S et al. Use of opioïd analgesis in the treatment of cancer pain: evidence-based recommendations from the EAPC. Lancet Oncol 2012; 13:e58-e68.
Caraceni A, Pigni A, Brunelli C. Is oral morphine still the first choice opioid for moderate to severe cancer pain?

(Hannaford 2010) Hannaford PC, Iversen L, Macfarlane TV et al. Mortality among contraceptive pill users: cohort evidence from
(Hannaford 2010) Hannaford PC, Iversen L, Macfarlane TV et al. Mortality among contraceptive pill users: cohort evidence from Royal College

[20] S. Gress, A. Focke, F. Hessel, and J. Wasem, Financial incentives for disease management programmes and integrated care in German social health insurance., Health policy (Amsterdam, Netherlands), vol. 78, no. 2-3, pp. 295-305, Oct. 2006. [21] S. Gress, P. Groenewegen, J. Kerssens, B. Braun, and J. Wasem, Free choice of sickness funds in regulated competition: evidence from Germany and The Netherlands., Health policy, vol. 60, no. 3, pp. 235-54, Jun. 2002. [22] D. Grijpstra, S. Broek, B.-J.
44-55, 2001. [20] S. Gress, A. Focke, F. Hessel, and J. Wasem, Financial incentives for disease management programmes and integrated care in German social health insurance., Health policy (Amsterdam, Netherlands), vol.

Table 5: Update of evidence found in SR and HTA Search Radiation harms of mammography screening (40-49 y) questions Note Update of HTA (ETMIS) Date 03/05/2010 Keywords Breast neoplasms, mammography/ adverse effects, mass screening/ adverse effects Medline Case report.tw (156081) (OVID): 2 Letter.pt (689184) Filter 3 Historical article.pt (263481) RCT 4 Review of reported cases.pt (0) 5 Review,multicase.pt (0) 6 or/1-5 (1099551) 7 Breast/ or Breast Diseases/ (30731) 8 Neoplasms/ (216844) 9 7 and 8 (536) 10 exp Breast Neoplasms/ (171800) 11 (breast$ adj5 neoplas$).tw (2557) 12 (breast$ adj5 cancer$).tw (135752) 13 (breast$ adj5 carcin$).tw (31777) 14 (breast$ adj5 tumo$).tw (23441) 15 (breast$ adj5 metasta$).tw (16582) 16 (breast$ adj5 malig$).tw (7361) 17 exp Carcinoma, Ductal, Breast/ (8472) 18 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 (207367) 19 Mammography/ae [Adverse Effects] (517) 20 Mass Screening/ae [Adverse Effects] (325) 21 19 or 20 (763) 22 18 and 21 (443) 23 22 not 6 (379) 24 limit 23 to (yr=" 2005 -Current" and " all adult (19 plus years)" and (dutch or english or french)) (44) 25 from 24 keep 1-44 (44)
Table 3: Update of evidence found in SR and HTA Search Radiation harms of mammography screening (40-49 y) questions Note Update of HTA (ETMIS) Date 03/05/2010 Keywords Breast neoplasms, mammography/ adverse effects, mass screening/ adverse effects Medline Case report.tw (156081) (OVID): 2 Letter.pt (689184) Filter 3 Historical article.pt (263481) RCT 4 Review of reported cases.pt (0) 5 Review,multicase.pt (0) 6 or/1-5 (1099551) 7 Breast/ or Breast Diseases/ (30731) 8 Neoplasms/ (216844) 9 7 and 8 (536) 10 exp Breast Neoplasms/ (171800) 11 (breast$ adj5 neoplas$).tw (2557) 12 (breast$ adj5 cancer$).tw (135752) 13 (breast$ adj5 carcin$).tw (31777) 14 (breast$ adj5 tumo$).tw (23441) 15 (breast$ adj5 metasta$).tw (16582) 16 (breast$ adj5 malig$).tw (7361) 17 exp Carcinoma, Ductal, Breast/ (8472) 18 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 (207367) 19 Mammography/ae [Adverse Effects] (517) 20 Mass Screening/ae [Adverse Effects] (325) 21 19 or 20 (763) 22 18 and 21 (443) 23 22 not 6 (379) 24 limit 23 to (yr=" 2005 -Current" and " all adult (19 plus years)" and (dutch or english or french)) (44) 25 from 24 keep 1-44 (44)

40% of the candidate surgeons were excluded from the ACST trial, while they probably did not stop treating patients. 50 To be eligible, participating surgeons had to show evidence of their last 50 CEAs.
40% of the candidate surgeons were excluded from the ACST trial, while they probably did not stop treating patients.50 To be eligible, participating surgeons had to show evidence of their last 50 CEAs.

For primary prevention of stroke, adequate blood pressure reduction, and treatment of hyperlipidemia, use of antithrombotic therapy in patients with atrial fibrillation and of antiplatelet therapy in patients with myocardial infarction are effective and supported by evidence from several
For primary prevention of stroke, adequate blood pressure reduction, and treatment of hyperlipidemia, use of antithrombotic therapy in patients with atrial fibrillation and of antiplatelet therapy in patients with myocardial infarction are effective and supported by evidence from several randomized trials.1 Effective strategies for the secondary prevention of stroke include